BioSpace News Archive

A member of the faculty at San Diego Academy of Regenerative Therapies (SDARTs) has published an important paper addressing pulmonary and respiratory therapies for patients who have suffered from the nCoV-2 Coronavirus.

Sengenics, the Functional Proteomics Company, announced today that it has entered into a research collaboration agreement with GlaxoSmithKline (GSK).

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tacrolimus Inhalation Powder for prophylaxis of lung allograft rejection. Tacrolimus Inhalation P

The Marena Group LLC, a Georgia-based medical device manufacturer, announced that it has immediately begun producing new non-surgical masks for children in response to the COVID-19 pandemic.

The Urology Care Foundation, the official foundation of the American Urological Association, announced Arthur L. “Bud” Burnett, II, MD has been named to the Urology Care Foundation Board of Directors.

Researchers at Montefiore Health System and Albert Einstein College of Medicine, in collaboration with four major New York City academic health centers, published the largest review to date of birth outcomes among women with SARS-CoV-2, the novel coronavirus.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced a collaboration with the American Society of Hematology (ASH), the world’s largest professional society of hematologists, to support a new effort to increase capacity for newborn screening, education, and cli

In what is planned to be an ever-growing resource for laboratory informatics professionals everywhere, CSols, Inc., the premier laboratory informatics consultancy, has launched CSols University, with its first-ever online course, Creating a Lab Informatics Risk Assessment.

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta®, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty drugs.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions using the latest biotechnology, today announced that the U.S. Food and Drug Administration (FDA) has approved Crysvita®